Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials

Linda G. Mellbin, Deepak L. Bhatt, Jens Peter David, Kathrine Ekström, Mark C. Petrie, Søren Rasmussen, Tina Vilsbøll

Research output: Contribution to journalArticlepeer-review

5 Scopus citations
Original languageEnglish
Pages (from-to)1371-1374
Number of pages4
JournalEuropean Heart Journal
Volume45
Issue number15
DOIs
StatePublished - 14 Apr 2024

Keywords

  • Cardiovascular outcomes trial
  • Glucagon-like peptide-1 receptor agonist
  • HbA
  • Major adverse cardiovascular events
  • PIONEER 6
  • Post hoc analysis
  • SUSTAIN 6
  • Semaglutide
  • Type 2 diabetes

Cite this